Outcomes of lung transplantation in patients with scleroderma

Malek G. Massad, Charles Powell, Jacques Kpodonu, Cimenga Tshibaka, Ziad Hanhan, Norman J. Snow, Alexander S. Geha

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Patients with pulmonary insufficiency due to scleroderma have long been considered suboptimal candidates for lung transplantation. This has been supported by small single-center experiences that did not reflect the entire U.S. experience. We sought to evaluate the outcome of patients with scleroderma who underwent lung transplantation. We conducted a retrospective review of 47 patients with scleroderma who underwent lung transplantation at 23 U.S. centers between 1987 and 2004 and were reported to the United Network for Organ Sharing. Women constituted 57% of the patients. The mean age was 46 years. Twenty-seven patients received single lung transplants (57%), and the remaining received double lung transplants. The mean cold ischemia time was 4.1 hours. There were 7 early deaths (≤30 days) and 17 late deaths (> 30 days). The causes of early death were primary graft failure and a cardiac event in two patients each and bacterial infection and stroke in one patient each. Late mortality was due to infection in seven patients, respiratory failure in three, malignancy in two, and multisystem organ failure, rejection, pulmonary hypertension, and a cardiac event in one patient each. The causes of early and late death were not recorded for two patients. One patient received a second transplant owing to graft failure of the first. Twenty-three patients (49%) were alive at a mean follow-up of 24 months. The Kaplan-Meier 1- and 3-year survival rates were 67.6% and 45.9% respectively, which are not significantly different from those of 10,070 patients given transplants for other lung conditions during the same period (75.5% and 58.8% respectively, P = 0.25). Donor gender, recipient's age, and type of transplant did not affect survival. In carefully selected patients with scleroderma who have end-stage lung disease, lung transplantation is a valid life-saving therapeutic option. Available data suggest acceptable short-term morbidity and mortality and a long-term survival similar to that of patients given transplants for other lung conditions.

Original languageEnglish (US)
Pages (from-to)1510-1515
Number of pages6
JournalWorld Journal of Surgery
Volume29
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Lung Transplantation
Transplants
Lung
Cold Ischemia
Survival
Mortality
Bacterial Infections
Pulmonary Hypertension
Respiratory Insufficiency
Lung Diseases

ASJC Scopus subject areas

  • Surgery

Cite this

Massad, M. G., Powell, C., Kpodonu, J., Tshibaka, C., Hanhan, Z., Snow, N. J., & Geha, A. S. (2005). Outcomes of lung transplantation in patients with scleroderma. World Journal of Surgery, 29(11), 1510-1515. https://doi.org/10.1007/s00268-005-0017-x

Outcomes of lung transplantation in patients with scleroderma. / Massad, Malek G.; Powell, Charles; Kpodonu, Jacques; Tshibaka, Cimenga; Hanhan, Ziad; Snow, Norman J.; Geha, Alexander S.

In: World Journal of Surgery, Vol. 29, No. 11, 11.2005, p. 1510-1515.

Research output: Contribution to journalArticle

Massad, MG, Powell, C, Kpodonu, J, Tshibaka, C, Hanhan, Z, Snow, NJ & Geha, AS 2005, 'Outcomes of lung transplantation in patients with scleroderma', World Journal of Surgery, vol. 29, no. 11, pp. 1510-1515. https://doi.org/10.1007/s00268-005-0017-x
Massad, Malek G. ; Powell, Charles ; Kpodonu, Jacques ; Tshibaka, Cimenga ; Hanhan, Ziad ; Snow, Norman J. ; Geha, Alexander S. / Outcomes of lung transplantation in patients with scleroderma. In: World Journal of Surgery. 2005 ; Vol. 29, No. 11. pp. 1510-1515.
@article{6757588d69a14120b4af7e4ac4818b00,
title = "Outcomes of lung transplantation in patients with scleroderma",
abstract = "Patients with pulmonary insufficiency due to scleroderma have long been considered suboptimal candidates for lung transplantation. This has been supported by small single-center experiences that did not reflect the entire U.S. experience. We sought to evaluate the outcome of patients with scleroderma who underwent lung transplantation. We conducted a retrospective review of 47 patients with scleroderma who underwent lung transplantation at 23 U.S. centers between 1987 and 2004 and were reported to the United Network for Organ Sharing. Women constituted 57{\%} of the patients. The mean age was 46 years. Twenty-seven patients received single lung transplants (57{\%}), and the remaining received double lung transplants. The mean cold ischemia time was 4.1 hours. There were 7 early deaths (≤30 days) and 17 late deaths (> 30 days). The causes of early death were primary graft failure and a cardiac event in two patients each and bacterial infection and stroke in one patient each. Late mortality was due to infection in seven patients, respiratory failure in three, malignancy in two, and multisystem organ failure, rejection, pulmonary hypertension, and a cardiac event in one patient each. The causes of early and late death were not recorded for two patients. One patient received a second transplant owing to graft failure of the first. Twenty-three patients (49{\%}) were alive at a mean follow-up of 24 months. The Kaplan-Meier 1- and 3-year survival rates were 67.6{\%} and 45.9{\%} respectively, which are not significantly different from those of 10,070 patients given transplants for other lung conditions during the same period (75.5{\%} and 58.8{\%} respectively, P = 0.25). Donor gender, recipient's age, and type of transplant did not affect survival. In carefully selected patients with scleroderma who have end-stage lung disease, lung transplantation is a valid life-saving therapeutic option. Available data suggest acceptable short-term morbidity and mortality and a long-term survival similar to that of patients given transplants for other lung conditions.",
author = "Massad, {Malek G.} and Charles Powell and Jacques Kpodonu and Cimenga Tshibaka and Ziad Hanhan and Snow, {Norman J.} and Geha, {Alexander S.}",
year = "2005",
month = "11",
doi = "10.1007/s00268-005-0017-x",
language = "English (US)",
volume = "29",
pages = "1510--1515",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Outcomes of lung transplantation in patients with scleroderma

AU - Massad, Malek G.

AU - Powell, Charles

AU - Kpodonu, Jacques

AU - Tshibaka, Cimenga

AU - Hanhan, Ziad

AU - Snow, Norman J.

AU - Geha, Alexander S.

PY - 2005/11

Y1 - 2005/11

N2 - Patients with pulmonary insufficiency due to scleroderma have long been considered suboptimal candidates for lung transplantation. This has been supported by small single-center experiences that did not reflect the entire U.S. experience. We sought to evaluate the outcome of patients with scleroderma who underwent lung transplantation. We conducted a retrospective review of 47 patients with scleroderma who underwent lung transplantation at 23 U.S. centers between 1987 and 2004 and were reported to the United Network for Organ Sharing. Women constituted 57% of the patients. The mean age was 46 years. Twenty-seven patients received single lung transplants (57%), and the remaining received double lung transplants. The mean cold ischemia time was 4.1 hours. There were 7 early deaths (≤30 days) and 17 late deaths (> 30 days). The causes of early death were primary graft failure and a cardiac event in two patients each and bacterial infection and stroke in one patient each. Late mortality was due to infection in seven patients, respiratory failure in three, malignancy in two, and multisystem organ failure, rejection, pulmonary hypertension, and a cardiac event in one patient each. The causes of early and late death were not recorded for two patients. One patient received a second transplant owing to graft failure of the first. Twenty-three patients (49%) were alive at a mean follow-up of 24 months. The Kaplan-Meier 1- and 3-year survival rates were 67.6% and 45.9% respectively, which are not significantly different from those of 10,070 patients given transplants for other lung conditions during the same period (75.5% and 58.8% respectively, P = 0.25). Donor gender, recipient's age, and type of transplant did not affect survival. In carefully selected patients with scleroderma who have end-stage lung disease, lung transplantation is a valid life-saving therapeutic option. Available data suggest acceptable short-term morbidity and mortality and a long-term survival similar to that of patients given transplants for other lung conditions.

AB - Patients with pulmonary insufficiency due to scleroderma have long been considered suboptimal candidates for lung transplantation. This has been supported by small single-center experiences that did not reflect the entire U.S. experience. We sought to evaluate the outcome of patients with scleroderma who underwent lung transplantation. We conducted a retrospective review of 47 patients with scleroderma who underwent lung transplantation at 23 U.S. centers between 1987 and 2004 and were reported to the United Network for Organ Sharing. Women constituted 57% of the patients. The mean age was 46 years. Twenty-seven patients received single lung transplants (57%), and the remaining received double lung transplants. The mean cold ischemia time was 4.1 hours. There were 7 early deaths (≤30 days) and 17 late deaths (> 30 days). The causes of early death were primary graft failure and a cardiac event in two patients each and bacterial infection and stroke in one patient each. Late mortality was due to infection in seven patients, respiratory failure in three, malignancy in two, and multisystem organ failure, rejection, pulmonary hypertension, and a cardiac event in one patient each. The causes of early and late death were not recorded for two patients. One patient received a second transplant owing to graft failure of the first. Twenty-three patients (49%) were alive at a mean follow-up of 24 months. The Kaplan-Meier 1- and 3-year survival rates were 67.6% and 45.9% respectively, which are not significantly different from those of 10,070 patients given transplants for other lung conditions during the same period (75.5% and 58.8% respectively, P = 0.25). Donor gender, recipient's age, and type of transplant did not affect survival. In carefully selected patients with scleroderma who have end-stage lung disease, lung transplantation is a valid life-saving therapeutic option. Available data suggest acceptable short-term morbidity and mortality and a long-term survival similar to that of patients given transplants for other lung conditions.

UR - http://www.scopus.com/inward/record.url?scp=28244472761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244472761&partnerID=8YFLogxK

U2 - 10.1007/s00268-005-0017-x

DO - 10.1007/s00268-005-0017-x

M3 - Article

C2 - 16222454

AN - SCOPUS:28244472761

VL - 29

SP - 1510

EP - 1515

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 11

ER -